PBMD News 1.04 Prima Biomed Ltd (PBMD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Prima Biomed Ltd (PBMD) 1.04 $PBMD

Prima BioMed to Present at 13th Annual Needham Healthcare Conference
Marketwire - Sun Apr 06, 8:30PM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company" today announced that its Chief Executive Officer, Matthew Lehman, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. U.S. Eastern time (corresponds to Thursday, April 10 at 4:20 a.m. in Sydney) in New York City. Mr. Lehman will provide a Company overview and update on recent activities.

Prima BioMed's CVac(TM) Data Demonstrating Improvement in PFS in Second Remission Ovarian Cancer Accepted for Oral Presentation at ASCO
Marketwire - Thu Mar 27, 8:40PM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" announced today that the American Society of Clinical Oncology has accepted the abstract entitled, "Progression-free survival in ovarian cancer patients in second remission is improved with mucin-1 autologous dendritic cell therapy" for oral presentation at the Gynecologic Cancer Session at the 2014 ASCO Annual Meeting to be held May 30 - June 3, 2014 in Chicago.

Prima BioMed Announces Significant Updates to Its Clinical Advisory Board: Eric Pujade-Lauraine, Christian Marth, and Ignace Vergote Join Esteemed Group of Gynecology Oncology Advisors
Marketwire - Tue Mar 25, 8:39AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company" announced today that Professors Eric Pujade-Lauraine, MD, PhD, Christian Marth, MD, PhD, and Ignace Vergote MD, PhD have joined Prima's Clinical Advisory Board to advise on the Company's development of CVac(TM) for the treatment of epithelial ovarian cancer. These esteemed researchers and clinicians join Prima's existing clinical advisory board members Jonathon Berek and Bradley Monk in the United States, Walther Kuhn in Germany, and Jeffrey Goh in Australia.

$1.6 Million R&D Tax Incentive Refund Received
Marketwire - Wed Mar 05, 8:26AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the Company" is pleased to advise that it has received approximately $1.6 million in cash rebate from the Australian federal government's R&D tax incentive program. The cash rebate was provided essentially in respect of expenditure incurred on eligible Australian R&D activities conducted on the CVac clinical trials during the 2013 financial year.

Global Psoriasis Drug Forecast and Market Analysis to 2022 - Sales by region
M2 - Thu Feb 27, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/bkkwwm/pharmapoint) has announced the addition of the "PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022" report to their offering. 2012 PsO drug sales to be $5.6 billion across the nine major markets (9MM) covered in this report: US, France, Germany, Italy, Spain, UK, Japan, China, and India. By forecast end in 2022, sales will increase to over $7.62 billion at a Compound Annual Growth Rate (CAGR) of 3.1%, which includes seven pipeline therapies and the launch of biosimilars. This growth will be driven by: - The launch of novel PsO products, such as Eli Lilly's ixekizumab, Amgen's brodalumab, Novartis' secukinumab, Merck's MK-3222, Pfizer's Xeljanz (tofacitinib), Celgene's apremilast, and Biocon's Alzumab (itolizumab) - The uptake of biosimilars for the currently marketed biologics: etanercept, adalimumab, infliximab, and ustekinumab - Increased access to PsO biologics in China and India Despite these drivers, the PsO market will be crowded, yet comprised of diversified therapies. Individual drugs will struggle to gain a foothold as they distinguish themselves from each other. Unmet Needs in Psoriasis While dermatologists agree that the current biologics have revolutionized the PsO landscape, there is a dire need for therapies that can provide long-lasting effects, without side effects or an increased risk of comorbidities. The current pipeline includes at least four novel therapies that have exceptionally high clinical efficacy and good safety profiles, and these include: Novartis' secukinumab, Amgen's brodalumab, Merck's MK-3222, and Eli Lilly's ixekizumab. The dosing schedule for these therapies is quite convenient, as some of them are dosed once monthly and four times a year on average. Interestingly, of the seven pipeline products, three are me-too biologics, each of which targets the cytokine interleukin-17 (IL-17). However, we expect Novartis' inhibitor to be the first of this group to launch in 2014. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AbbVie (Abbott) - Johnson & Johnson - Novartis - Pfizer - Eli Lilly - Merck - LEO Pharma - Celgene For more information visit http://www.researchandmarkets.com/research/bk...harmapoint

Prima BioMed to Present at Regen Med Investor Day March 26th in New York
Marketwire - Wed Feb 26, 7:15PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company" will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.

Prima BioMed to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 4:30PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company" will present a corporate overview and provide an update of its CVac(TM) development program at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York City on Monday, March 3rd at 1:35 p.m. (U.S. Eastern Standard Time).

Prima BioMed enters into final license agreement for CVac with Neopharm Group in Israel and the Palestinian Authority
M2 - Fri Feb 21, 4:46AM CST
Therapeutic products company Prima BioMed (ASX RR) (NASDAQ BMD) said on Thursday that it has finalised its exclusive agreement to license, market and sell CVac in Israel and the Palestinian Authority, for the treatment of epithelial ovarian cancer.

Prima BioMed and Neopharm Group Execute Final Agreement for CVac License
Marketwire - Thu Feb 20, 4:09PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" is pleased to announce that it has finalized an agreement with Neopharm Group ("Neopharm" for an exclusive license ("License" to market and sell CVac(TM), a personalized immunocellular therapeutic under investigation for the treatment of epithelial ovarian cancer, in Israel and the Palestinian Authority.

Prima BioMed names Dr Bradley J. Monk to clinical advisory board
M2 - Thu Feb 20, 9:11AM CST
Immunocellular therapeutic company Prima BioMed Ltd (ASX RR) (NASDAQ BMD) reported on Wednesday the addition of Dr Bradley J. Monk, MD, to its clinical advisory board, with responsibility for the development of CVac for the treatment of epithelial ovarian cancer.

Dr. Bradley J. Monk to Join Prima BioMed's Clinical Advisory Board
Marketwire - Wed Feb 19, 6:05PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company" announced today that Bradley J. Monk, MD, an esteemed clinical researcher and practicing gynecological oncologist, has joined Prima's Clinical Advisory Board to advise the Company's development of CVac(TM) for the treatment of epithelial ovarian cancer.

Prima BioMed Ltd names Pete A Meyers to board
M2 - Wed Feb 12, 3:09AM CST
Therapeutic company Prima BioMed Ltd (ASX RR) (NASDAQ BMD) revealed on Tuesday the addition of Pete A Meyers as non-executive director of the board with immediate effect.

Pete A. Meyers to Join Prima BioMed's Board of Directors
Marketwire - Tue Feb 11, 5:45PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" is pleased to announce that Pete A. Meyers will join Prima's Board as a Non-Executive Director with immediate effect.

Prima BioMed's CAN-004 Clinical Trial Amendment Approved in Multiple Jurisdictions
Marketwire - Wed Feb 05, 4:00PM CST
Prima BioMed Ltd. (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company" announced that multiple jurisdictions have approved its amended CAN-004 protocol including regulators in Latvia, Lithuania, Bulgaria, Ukraine and Belarus. As previously announced, the CAN-004 trial was approved by the Belgian regulators in January 2014.

Source Exploration Corp. Announces Adoption of Advance Notice-By-Law and Retains Transcend Resource Group for Investor Relations Services
Marketwire Canada - Mon Feb 03, 12:52PM CST
Source Exploration Corp. (the "Corporation" (TSX VENTURE:SOP) today announced that its board of directors (the "Board" has approved an amendment to the by-laws of the Corporation (By-Law No. 1) to include mandatory procedures for nominations of persons for election to the Board, including an advance notice requirement for nominations of directors by shareholders in certain circumstances (the "By-Law Amendment" .

Prima BioMed to Present at the 16th Annual BIO CEO & Investor Conference
Marketwire - Thu Jan 30, 8:20PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company" has announced today that Matthew Lehman, its Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Monday, 10 February 2014 in New York City at the Waldorf Astoria Hotel. Mr. Lehman will provide an overview of the Company and its corporate activities and will be available to participate in one-on-one meetings.

Prima BioMed Second Quarter Highlights and Management Conference Call
Marketwire - Wed Jan 29, 7:05AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company" today released its Appendix 4C - Quarterly Report for the second quarter of financial year 2014, the three month period ending 31 December 2013.

Prima BioMed's CAN-004 Clinical Trial Amendment Approved in Belgium
Marketwire - Fri Jan 17, 7:01AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company" today announced that the amended CAN-004 protocol was approved by the Belgian Federal Agency for Medicines and Health Products. This is the first regulatory agency to approve the amended CVac(TM) clinical trial design. CAN-004 is a multicentre, randomized, phase 2 trial of CVac for the maintenance treatment of epithelial ovarian cancer in remission.

5 Under-$10 Biotech Stocks to Watch
at The Street - Fri Jan 10, 6:00AM CST
Keep these biotech stocks on your radar.

Prima BioMed CEO Matthew Lehman to Be Interviewed on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Thu Jan 09, 7:52AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" , a leader in developing personalized immunocellular therapies for the treatment of cancer, announced today that CEO Matthew Lehman will be interviewed live by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 106

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 156

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 79

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 56

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 89

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 221

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 16

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 85

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 88

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 85

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Steers Focus Towards Asia's Streaming Landscape Success

Updated Category News Views 192

Disney Enters the Competitive Asian Streaming Market Walt Disney Co (NYSE: DIS) is strategically positioning itself to dominate in the vibrant Asian streaming market. The company's latest initiative involves a significant investment in original Japanese anime, alongside the expansion of its Korean superhero franchise. With this bold move, Disney aims to establish a strong...

Continue Reading
MSSA and GSMA Unite to Expand Mobile Satellite Services

Updated Category News Views 81

Strategic Alliance of MSSA and GSMA The Mobile Satellite Services Association (MSSA) has announced an exciting new partnership with the GSMA, a leading global organization dedicated to mobile operators and the broader mobile ecosystem. This synergy aims to elevate mobile technology to new heights and transform the landscape of mobile satellite communications. Advancing...

Continue Reading
Celebrating Pioneers: 2025 XCEL Summit for Men Highlights Heroes

Updated Category News Views 259

Honoring Leadership at the 2025 XCEL Summit for Men Black Enterprise is excited to showcase the remarkable individuals receiving the prestigious XCEL Awards at the much-anticipated XCEL Summit for Men. This year's celebration promises to be a hallmark event, scheduled for mid-October at the Hyatt Regency Grand Cypress in Orlando. Attendees can expect a magnificent...

Continue Reading
Innovative Trial Launches to Combat Pediatric Leukemia Worldwide

Updated Category News Views 259

Revolutionizing Pediatric Leukemia Treatment The Leukemia & Lymphoma Society (LLS) has embarked on an extraordinary journey with the launch of the PedAL (Pediatric Acute Leukemia) Master Clinical Trial, a trailblazing effort that marks the world's first-ever global trial focused on menin inhibitors for treating pediatric leukemia. This initiative is part of LLS's broader...

Continue Reading
Aflac Partners with Workday to Enhance Employee Benefits Experience

Updated Category News Views 196

Aflac's Collaboration with Workday for Enhanced Wellness Solutions Aflac, a prominent provider of supplemental insurance in the U.S., has entered into a partnership with Workday Wellness aimed at revolutionizing employee benefit offerings. This strategic relationship empowers employers to provide a more personalized experience for their workforce, ultimately aimed at...

Continue Reading